Mostrar el registro sencillo del documento
Contingent assessment of the COVID-19 vaccine
dc.creator | García, Leidy Y. | |
dc.creator | Cerda, Arcadio A. | |
dc.date.accessioned | 2020-09-28T16:28:00Z | |
dc.date.available | 2020-09-28T16:28:00Z | |
dc.date.created | 2020 | |
dc.identifier.issn | 0264-410X | spa |
dc.identifier.other | https://doi.org/10.1016/j.vaccine.2020.06.068 | spa |
dc.identifier.uri | http://hdl.handle.net/20.500.12010/13907 | |
dc.description.abstract | The COVID-19 pandemic has not only had a negative impact on people’s health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual’s willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (p 0:05), knowledge of COVID-19 (p 0:05), being sick with COVID-19 (p 0:05), perception of government performance (p 0:01), employment status (p 0:01), income (p 0:01), health care (p 0:05), adaptation to quarantine with children at home (p 0:01Þ and whether the person has recovered from COVID-19 (p 0:10Þ. According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals’ WTP is US$184.72 (CI: 165.52–203.92; p < 0.01). This implies a social valuation of approximately US$2232 million, corresponding to 1.09% of the GNP per capita. | spa |
dc.format.extent | 6 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Vaccine | spa |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
dc.subject | COVID-19 | spa |
dc.subject | SARS-CoV-2 | spa |
dc.subject | Vaccine | spa |
dc.subject | Acceptance | spa |
dc.subject | Health economics | spa |
dc.subject | Contingent valuation | spa |
dc.title | Contingent assessment of the COVID-19 vaccine | spa |
dc.type.local | Artículo | spa |
dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
dc.subject.lemb | COVID-19 | spa |
dc.subject.lemb | SARS-CoV-2 | spa |
dc.subject.lemb | Coronavirus | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.identifier.doi | https://doi.org/10.1016/j.vaccine.2020.06.068 | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
Archivos en el documento
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este documento. |